

**24th Meeting of the EWALL
Frankfurt
16. /17. November 2012**

16. November 2012: 17:00 – 20:00

16:30	Arriving and Coffee Time		Minutes per talk
17:00 – 18:30	Ph-positive ALL – Part I		
	Standardization and quality control of bcr-abl analysis; Euro MRD consortium	H.Pfeifer	10
	Update Ph-01 Study – Dasatinib in Elderly	P.Rousselot	10
	Nilotinib and Imatinib in rotation (GIMEMA trial)	C.Papayanidis	10
	Update: Ponatinib in elderly	G.Martinelli	10
	Imatinib followed by chemotherapy – first line and update on the ongoing GIMEMA Dasatinib trial	S.Chiaretti	10
	New joint projects		
	European registry for elderly ALL	N.Gökbuget	10
18:30-20:00	PEG-asparaginase in adult ALL (sponsored by Sigma Tau)		
18:35 – 18:45	Overview of the company and pipeline	M.Brughera	10
18:45-19:00	PEG – Asparaginase and Oncaspar®: Today and the future? An overview on compound and manufacture's aspects	G.Fornasini	15
19:00-19:15	EZN2285 – a follow-up compound of Oncaspar®: A clinical review	T. Keilani	15
19:15 – 19:55	The use and future of PEG – Asparaginase in different European countries and their related study groups France: HerveDombret Spain: Josep Ribera Italy: Renato Bassan Germany: Nicola Gökbuget UK: Adele Fielding	Moderation: D. Hoelzer	40
20:00-20:30	Aperitifs		

20:30 Dinner at Forsthaus Restaurant

17. November 2012: 08:30-13:00

	Breakfast		Minutes per talk
08:30-9:45	Inotuzumab trials in relapsed ALL (sponsored by Pfizer)		
	Results from Pfizer Phase I studies with Inotuzumab and further plans for clinical development	E.Vandendries	10+15
	Comments and Discussion	All	
	Inotuzumab Phase III trial in relapsed/refr. ALL	E.Vandendries	10+20
	Current status	U.Zacharias ICON	
	Problems and pitfalls	All	
	Possibilities for EWALL support in the different countries	All	
	New options for collaboration between Pfizer and EWALL members	All	20
	Discussion		
10:00-10:15	Coffee break		
10:15-11:15	Blinatumomab trials and projects (sponsored by AMGEN)		
	<u>Welcome and introduction</u>		5
	Overview on Historical Comparator Trials for Blinatumomab (AMG103)		
	Purpose of the meeting		
	<u>20120148 - MRD-positive ALL Historical Comparator Trial</u>		35
	Presentation of the final study design		
	Trial Steering Committee Charter and publication policy		
	Next steps		
	<u>20120310 – Relapsed / refractory (RR) ALL Historical Comparator Trial</u>		20
	Overview of study rationale and objectives		
	Patient population: geographic regions, inclusion/exclusion criteria		
	Operational considerations		

11:15 – New drugs and approaches in ALL

13:00

Ph-positive ALL: Part II

Randomized posttransplant study Nilotinib vs Dasatinib O.Ottmann 10

Status of the Ph-02 study: Nilotinib in elderly O.Ottmann 10

New approaches in ALL

Monosomal karyotype in adult ALL A.Rijneveld, M.Hunault, H.Dombret 10

GIMEMA study for young adults up to 35 years A.Testi 10

First experience with PEG-asparaginase in first-line A.Fielding 10

Clofarabine in 1st line treatment of adult ALL A.Rijneveld 5

Monosomal karyotype in ALL A.Rijneveld, M.Hunault, H.Dombret 10

Forthcoming meetings

EHA-SWG D.Hoelzer 10

Programme EWALL meetings 2013

Programme for EHA 2013

EHA-SWG Symposium 2014 Plenum

13:00 Lunch and adjourn
